Company Long-Term Liabilities: MeiraGTx Holdings (MGTX)

Graphic logo of MeiraGTx Holdings (MGTX)

Due to its monopoly position in treating rare pathologies, MeiraGTx Holdings plc (MGTX) exercises significant pricing power, as evidenced by the market price action on GURU.Markets with the 0.12 indicator. The business relies on AI-driven regulation of gene expression and a partnership with Sanofi to develop its ophthalmology pipeline. Stability is guaranteed by its own vector manufacturing plants, which integrate scientific research with high-capacity production.

MeiraGTx (MGTX) Company Long-Term Debts: for the period 07/04/2022 - 11/01/2026

MeiraGTx PLC (MGTX) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price meiragtx.com|MGTX - Price Target Chart
- company stock exchange capitalization indicators:
Market Valuation MeiraGTx|MGTX - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share MeiraGTx|MGTX - Book Capitalization|Market Capitalization to Book Value meiragtx.com|MGTX - Aggregate Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio MeiraGTx Holdings plc|MGTX - Long-Term Debt to Capital|Short-Term Debt to Capital MeiraGTx Corp|MGTX - Company Aggregate Debts|Debt to Net Assets MeiraGTx|MGTX - Company Long-Term Liabilities|Amount of Current Liabilities MeiraGTx|Immediate Liquidity Ratio meiragtx.com
- earnings and market multiples details:
MGTX - Net Income
Summary company analytics:MGTX, meiragtx.com
Brand item of MeiraGTx PLC

MeiraGTx Holdings plc (MGTX) develops capital-intensive gene therapy technologies, where establishing proprietary production cycles requires significant long-term investment. By analyzing the company's long-term debt, an investor assesses the total volume of external obligations with a maturity of over one year, which determines financial stability when scaling proprietary developments. The dynamics of this metric allow for the timely detection of over-leverage risks or phases of active debt reduction.

Competitor analysis for MeiraGTx Holdings plc

Company Long-Term Debts Tempus Labs TEM|QGEN - Company Long-Term Debt|Ionis Pharmaceuticals, Inc. (IONS) - Company Long-Term Liabilities|RGEN: Company Long-Term Debts|Long-Term Debt Avidity Corp (RNA)|CRSP (CRISPR Therapeutics AG) - Company Long-Term Debts|genedx.com (WGS) - Long-Term Debt Volume|Company Long-Term Debt Ultragenyx (RARE)|BEAM (Beam Therapeutics Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts SRPT (Sarepta Therapeutics Inc)|Company Long-Term Debts Twist Bioscience Corp TWST|10x Genomics, Inc. - Company Long-Term Debts|Long-Term Indebtedness intelliatx.com (NTLA)|STOK (Stoke Therapeutics, Inc.) - Company Long-Term Liabilities|BLFS: Amount of Long-Term Liabilities|Company Long-Term Liabilities WVE|Company Long-Term Indebtedness MAZE (Maze Therapeutics Corp)|Company Long-Term Liabilities SION (Sionna Therapeutics Inc)|PRME (primemedicine.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts TSHA (Taysha Gene Therapies, Inc.)|Company Long-Term Loans and Borrowings QURE|RGNX - Company Long-Term Debt|Long-Term Debt Solid Corp|Ocugen, Inc. (OCGN) - Company Long-Term Debt|PACB (pacb.com) - Company Long-Term Debt|BNTC (Benitec Biopharma) - Company Long-Term Debts|Company Long-Term Indebtedness DSGN (Design Therapeutics Inc)|Company Long-Term Debts RCKT|Long-Term Debt Volume 4D Molecular Corp|Company Long-Term Debt Lexeo Therapeutics, Inc. LXEO|KRRO: Company Long-Term Indebtedness|Editas Medicine - Company Long-Term Debts|Long-Term Indebtedness Silence Therapeutics PLC (SLN)|proqr.com (PRQR) - Company Long-Term Debt|CDXS - Long-Term Debt Volume|Company Long-Term Liabilities SGMO|NAUT: Company Long-Term Loans and Borrowings|Company Long-Term Debt Metagenomi (MGX)|DTIL: Long-Term Liabilities|Company Long-Term Debt Generation Bio GBIO|Boundless Bio Inc - Company Long-Term Debt|Exicure Corp - Company Long-Term Debts|Imunon, Inc. (IMNN) - Company Long-Term Liabilities|phiopharma.com (PHIO) - Company Long-Term Debt|Company Long-Term Liabilities Mustang Bio|RNAZ (TransCode Therapeutics Inc.) - Company Long-Term Debts|BNGO - Long-Term Indebtedness|Company Long-Term Liabilities APDN (Applied DNA Sciences)|Amount of Long-Term Liabilities BLUE|ImmunoPrecise Antibodies Ltd. - Company Long-Term Liabilities|OMGA: Company Long-Term Indebtedness|Singular Genomics Systems Inc - Company Long-Term Debts|RGLS (Regulus) - Company Long-Term Indebtedness|Syros Pharmaceuticals (SYRS) - Company Long-Term Debt|Company Long-Term Indebtedness TBIO|TCON (TRACON Pharmaceuticals, Inc.) - Company Long-Term Debts|Company Long-Term Debts Unity Biotechnology Inc.